Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | VENICE I: venetoclax in R/R CLL patients

Arnon Kater • 8 Jun 2020
EHA 2020
Chronic Lymphocytic Leukemia Leukemia Venetoclax
VENICE I

Arnon Kater, MD, PhD, of the University of Amsterdam, Amsterdam, Netherlands, discusses the VENICE I trial (NCT02756611), a study investigating the efficacy of venetoclax in relapsed/refractory participants with chronic lymphocytic leukemia (CLL) including those with 17p deletion or tp53 mutation or those who have received a prior b-cell receptor inhibitor. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Arnon Kater

Epcoritamab monotherapy before chemoimmunotherapy in Richter’s transformation: Epcore CLL-1 1:48
Epcoritamab monotherapy before chemoimmunotherapy in Richter’s transformation: Epcore CLL-1
Arnon Kater • 6 Dec 2025
Epcoritamab in combination with R-CHOP or lenalidomide for Richter’s transformation 1:05
Epcoritamab in combination with R-CHOP or lenalidomide for Richter’s transformation
Arnon Kater • 6 Dec 2025
Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease 19:55
Updates to the ESMO CLL clinical practice guidelines: implications for relapsed disease
Arnon Kater et al. • 25 Apr 2025
GLOW trial updates: predicting outcomes using genomic aberrations and MRD status 2:28
GLOW trial updates: predicting outcomes using genomic aberrations and MRD status
Arnon Kater • 6 Oct 2023

Related Videos

MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR 7:15
MRD-guided treatment with ibrutinib and venetoclax in previously untreated CLL: analyses of FLAIR
Talha Munir • 16 Dec 2025
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax 2:14
Real-world outcomes of olutasidenib in IDH1-mutated AML previously treated with venetoclax
Jorge Cortes • 7 Dec 2025
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML 2:22
Patient-reported outcomes from ASC4FIRST study of asciminib in newly diagnosed CML
Jorge Cortes • 7 Dec 2025
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML 5:08
Preliminary human data and clinical implications of asciminib administration during pregnancy in CML
Elisabetta Abruzzese • 5 Dec 2025
The content of VJHemOnc is intended for healthcare professionals